Related Experiment Video
Updated: Jan 24, 2026

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
Published on: March 15, 2024
Modulatory effect of empagliflozin on cellular parameters of endocrine pancreas in experimental pre-diabetes
Ahmed A M Abdel-Hamid1, Alaa El-Din L Firgany2
1Department of Histology and Cell Biology, Faculty of Medicine, Mansoura University, Egypt.
Abstract:
The effect of empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on the structure of endocrine pancreas in pre-diabetes (Pre-DM) is not yet elucidated. In the current study the relatively enlarged islets of Langerhans seen in the Pre-DM group was restored to control size by administration of EMPA. In addition the disbalance in the percentage of β-cells and α-cells in islets of the Pre-DM was corrected in the Pre-DM + EMPA group with reversal of the significantly increased islet mass, β-cell mass and neogenesis. Administrating EMPA in Pre-DM decreased level of caspase-3, increased that of Bcl-2 to control level and reduced the significantly increased inflammatory cytokines to levels approximated to those of the control group. In Pre-DM + EMPA group, EMPA had efficiently restored the significantly impaired glucose hemostasis to levels nearly similar to those of the control animals. This may indicate that the modulatory effect of EMPA on cells of the islets in Pre-DM is associated with a local pleotropic effect on inflammatory cytokines.
Insights
Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), normalized enlarged pancreatic islets in pre-diabetes (Pre-DM). EMPA treatment corrected beta-cell mass and improved glucose homeostasis, suggesting a local anti-inflammatory effect.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Pre-diabetes (Pre-DM) is characterized by pancreatic islet structural changes.
- The therapeutic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i), such as empagliflozin (EMPA), on pancreatic islet structure in Pre-DM are not well understood.
Purpose of the Study:
- To investigate the impact of EMPA on the structural and cellular composition of pancreatic islets in a Pre-DM model.
- To evaluate the effects of EMPA on islet cell mass, neogenesis, apoptosis, and inflammatory markers in Pre-DM.
Main Methods:
- Administration of EMPA to a Pre-DM animal model.
- Histological analysis of pancreatic islets to assess size, islet mass, and cell composition (beta-cells and alpha-cells).
- Measurement of apoptotic markers (caspase-3, Bcl-2) and inflammatory cytokines.
Main Results:
- EMPA treatment restored enlarged islets of Langerhans to normal size in Pre-DM animals.
- EMPA corrected the imbalanced ratio of beta-cells and alpha-cells, reduced increased islet and beta-cell mass, and decreased neogenesis.
- EMPA administration normalized caspase-3 and Bcl-2 levels, and significantly reduced elevated inflammatory cytokines.
Conclusions:
- Empagliflozin effectively reverses structural and cellular abnormalities in pancreatic islets of Pre-DM.
- EMPA improves glucose homeostasis in Pre-DM, likely through local pleotropic effects on islet cells and reduction of inflammation.
More Related Videos
07:44Surgical Injury to the Mouse Pancreas through Ligation of the Pancreatic Duct as a Model for Endocrine and Exocrine Reprogramming and Proliferation
Published on: August 7, 2015
09:01Normothermic Ex Vivo Pancreas Perfusion for the Preservation of Pancreas Allografts before Transplantation
Published on: July 27, 2022
Related Concept Videos
Endocrine Signaling
Pancreas
The broad head of the pancreas lies within the loop formed by the duodenum, while its slender body reaches towards the spleen. The tail of the pancreas is short...
What is the Endocrine System?
The Endocrine System
An Overview of the Endocrine System
The endocrine system collaborates...
Structures of the Endocrine System